Drugs / NX-019
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05514496 | Oct 2022 → Jun 2025 overdue | — | Nalo Therapeutics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NX-019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05514496 ↗ |
| Route | Oral | “NX-019 will be administered orally.” NCT05514496 ↗ |